Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer
Mohammed H. Al-Qahtani, Mohammad Alam Jafri, Mourad Assidi, Abdelbaset Buhmeida, Peter Natesan Pushparaj, Maha Khalid Abdullah, Nofe Ateq Alganmi · 2026
Read Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer by Mohammed H. Al-Qahtani, Mohammad Alam Jafri, Mourad Assidi, Abdelbaset Buhmeida, Peter Natesan Pushparaj, Maha Khalid Abdullah, Nofe Ateq Alganmi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13547228.txt.
Description
Mohammed H. Al-Qahtani and colleagues screened a library of natural compounds wholly by computer in 2026, hunting for a breast cancer candidate that grips five cancer-driving proteins at once. Resistance often defeats single-target drugs, so one molecule gripping five targets could hold the line better. One compound, named 2-Aoeobenoxmide in the study, rose to the top across docking runs against the estrogen receptor and four growth-related enzymes.
Its predicted binding beat the approved drug tucatinib on every target, and long simulations suggested steadier, calmer complexes than the comparison drug formed. Checks of drug-like behavior and water effects also favored it. The authors stress that all of this is hypothesis until laboratory tests check the compound.
Catalog record
| CREATOR | Mohammed H. Al-Qahtani, Mohammad Alam Jafri, Mourad Assidi, Abdelbaset Buhmeida, Peter Natesan Pushparaj, Maha Khalid Abdullah, Nofe Ateq Alganmi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 132373 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |